ストックスクリーナーアプリを入手
20.43
7.27%
-1.765
前日終値:
$22.20
開ける：
$23.06
24時間の取引高:
44,204
Relative Volume:
0.47
時価総額：
$776.97M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-14.23%
1か月 パフォーマンス:
-32.49%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$19.96
$23.79
1週間の範囲:
$19.57
$25.04
52週間の値動き範囲:
$19.57
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
ORKA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ORKA | 20.43 | 776.97M | 0 | 0 | 0 | 0.00 |
| VRTX | 447.38 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.80 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.60 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.76 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Oruka Therapeutics Inc (ORKA) 最新ニュース
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference - The Manila Times
Oruka Therapeutics to Present at Piper Sandler Healthcare Conference | Psoriasis Drug Developer | ORKA Stock News - StockTitan
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference - GlobeNewswire
Oruka Therapeutics gains approval for preferred stock conversion - Investing.com
Oruka Therapeutics adjusts financials post-merger By Investing.com - Investing.com Canada
JANUS HENDERSON GROUP PLC Acquires New Stake in Oruka Therapeuti - GuruFocus.com
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Oruka Therapeutics Raises $475M, Accelerates Clinical Timeline for Key Drug Programs | ORKA Stock News - StockTitan
Oruka Therapeutics to Present at Multiple November Investor Conferences - StockTitan
Oruka stock draws buy rating at Stifel (NASDAQ:ORKA) - Seeking Alpha
Oruka Therapeutics shares gain buy rating as H.C. Wainwright sees strong future in psoriasis treatment - Investing.com Canada
Oruka Therapeutics Adjusts Executive Severance Agreements - TipRanks
Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga
Oruka shares rise as TD Cowen maintains buy on drug potential - Investing.com Canada
Oruka Therapeutics reveals promising preclinical data for psoriasis treatment - Investing.com
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of ... - The Bakersfield Californian
Oruka Therapeutics Announces Preclinical Data for ORKA-001 - GlobeNewswire
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - StockTitan
Ordell Minerals Advances Gold Prospects with Phase 2 Drilling - TipRanks
Orkla ASA (OTCMKTS:ORKLY) Sets New 1-Year High at $9.47 - Defense World
Orgenesis announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia
Orora (OTCMKTS:ORRYY) Shares Up 32.6% - Defense World
Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga
‘Omni Loop’ takes a bit too much on its plate - Daily Trojan Online
Private Auckland hospital doubles in size: New $3m robot, extra beds, surgical expansion - New Zealand Herald
Organon: A Surprising Deal (NYSE:OGN) - Seeking Alpha
‘Omni Loop’ (2024) Movie ReviewNothing New | MOVIESR.NET - Midgard Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Average PT from Analysts - Defense World
Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal
Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Leerink Partners - Defense World
Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Leerink Partnrs - Defense World
Ocugen Inc [OCGN] Stock bought by Insider RAMESH KUMAR for $0.15 million - Knox Daily
‘Omni Loop’ Review: Sci-Fi Indie Offers Some Ham-Fisted Heart - Observer
Lifesci Capital Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World
TD Cowen Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Leerink Partners starts drug developer Oruka with 'outperform' - XM
Oruka Therapeutics initiated with an Outperform at Leerink - TipRanks
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections - Benzinga
Roche scores first, with FDA approval of Ocrevus Zunovo for MS - The Pharma Letter
Analysts Issue Forecasts for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology
Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Jefferies Financial Group - Defense World
Oruka Therapeutics Secures $200M to Advance Skin Disease Treatments - TipRanks
FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - PR Newswire
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - STAT
Oruka to advance psoriasis programs into clinic next year - BioWorld Online
Jefferies starts Oruka Therapeutics with buy, $40 target - Investing.com UK
Biotech firm enters $200M agreement - The Business Journals
Oruka Therapeutics secures $200 million in PIPE financing By Investing.com - Investing.com Canada
Oruka Therapeutics Inc (ORKA) 財務データ
Oruka Therapeutics Inc (ORKA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Oruka Therapeutics Inc (ORKA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 24 '24 |
Buy |
3.20 |
189,856 |
606,873 |
2,081,168 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 25 '24 |
Buy |
3.05 |
30,227 |
92,292 |
2,111,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 03 '24 |
Buy |
3.55 |
166,042 |
589,565 |
1,648,577 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 11 '24 |
Buy |
3.45 |
94,537 |
326,304 |
1,891,312 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 10 '24 |
Buy |
3.46 |
55,463 |
192,130 |
1,796,775 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 08 '24 |
Buy |
3.46 |
47,492 |
164,190 |
1,724,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 05 '24 |
Buy |
3.43 |
28,326 |
97,065 |
1,676,903 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 09 '24 |
Buy |
3.43 |
16,917 |
58,091 |
1,741,312 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):